EAU Guidelines Strongly Recommend Aquablation Therapy for BPH
PRCT sits 31% above its 52-week low of $19.35.
Summary
The European Association of Urology (EAU) has upgraded its recommendation for PROCEPT BioRobotics' Aquablation therapy to a strong surgical recommendation for benign prostatic hyperplasia (BPH). This significant endorsement from one of the most influential global urology guideline bodies reflects robust clinical evidence supporting the therapy's efficacy and safety, particularly for preserving ejaculatory function. This upgrade is a major clinical validation for PROCEPT BioRobotics' core product, following the recent international launch of its HYDROS Robotic System and a Category I CPT code upgrade earlier this year. It is expected to drive increased adoption and market penetration for Aquablation therapy, positively impacting the company's revenue growth. Investors will watch for subsequent sales figures and further international guideline updates.
At the time of this announcement, PRCT was trading at $25.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $19.35 to $66.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.